Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer’s safety database

References

• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50:1091–1100.
   PubMed Web of Science ®Google Scholar
• Valentine JC, Morrissey CO, Tacey MA, et al. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005–2016. BMC Infect Dis. 2019;19:274.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Al-Obaidi M. Invasive fungal infections in the intensive care unit. Infect Dis Clin North Am. 2017;31:475–487.
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36:3043–3054.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, and Arikan-Akdagli S, et al. Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24:e1–e38.
   PubMed Web of Science ®Google Scholar
• Clark NM, Grim SA, Lynch JP 3rd. Posaconazole: use in the prophylaxis and treatment of fungal infections. Semin Respir Crit Care Med. 2015;36:767–785.
   PubMed Web of Science ®Google Scholar
• Assasi N, Grobelna A CADTH Rapid Response Reports. Posaconazole for the prophylaxis and treatment of invasive aspergillosis: a review of clinical effectiveness and guidelines. Version 1. July 13, 2017. https://www.cadth.ca/sites/default/files/pdf/htis/2017/RD0040_Posaconazole%20for%20Invasive%20Aspergillosis_Final.pdf. cited 2021 May 12.
   Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, and Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–347.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016;71:718–726.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Robertson MN, Haider S, et al. Pharmacokinetics and safety results from the phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017;72:3406–3413.
   PubMed Web of Science ®Google Scholar
• Fu R, Gundrum J, Sung AH. Health-care utilization and outcomes of patients at high risk of invasive fungal infection. Clinicoecon Outcomes Res. 2018;10:371–387.
   PubMed Web of Science ®Google Scholar
• Raschi E, Poluzzi E, Koci A, et al. Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014;6:601–612.
   PubMedGoogle Scholar
• Lo RV 3rd, Carbonari DM, Lewis JD, et al. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med. 2016;129:283–91.e5.
   PubMed Web of Science ®Google Scholar
• Kyriakidis I, Tragiannidis A, Munchen S, et al. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017;16:149–165.
   PubMed Web of Science ®Google Scholar
• Tverdek FP, Kofteridis D, Kontoyiannis DP. Antifungal agents and liver toxicity: a complex interaction. Expert Rev Anti Infect Ther. 2016;14:765–776.
   PubMed Web of Science ®Google Scholar
• Noxafil (posaconazole) injection, for intravenous use. Noxafil (posaconazole) delayed-release tablets, for oral use. Noxafil (posaconazole) oral suspension. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2021.
   Google Scholar
• Tverdek FP, Heo ST, Aitken SL, et al. Real-Life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses. Antimicrob Agents Chemother. 2017;61:e00188–17.
   PubMed Web of Science ®Google Scholar
• Perissinotti AJ, Marini BL. Managing liver dysfunction in haematology patients: switch antifungals, or use the tincture of time? Mycoses. 2019;62:214–216.
   PubMed Web of Science ®Google Scholar
• Pettit NN, Miceli MH, Rivera CG, et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017;72:2355–2358.
   PubMed Web of Science ®Google Scholar
• Shamsuddin H, Raudenbush CL, Sciba BL, et al. Evaluation of neural tube defects (NTDs) after exposure to raltegravir during pregnancy. J Acquir Immune Defic Syndr. 1999;2019:247–250.
   Google Scholar
• Woodward M, Marko A, Galea S, et al. Varicella virus vaccine live: a 22-year review of postmarketing safety data. Open Forum Infect Dis. 2019;1;6:ofz295.
   PubMed Web of Science ®Google Scholar
• Willis E, Woodward M, Brown EL, et al. Herpes zoster vaccine live: a 10 year review of post-marketing safety experience. Vaccine. 2017;35:7231–7239.
   PubMed Web of Science ®Google Scholar
• MedDRA. What’s new. MedDRA version 21.1. 9/2018;14. https://www.meddra.org/how-to-use/support-documentation/english. cited 2021 May 12.
   Google Scholar
• US Department of health and human services. Guidance for industry: postmarketing safety reporting for human drug and biological products including vaccines. 2001;1–50. https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Draft-Guidance-for-Industry–Postmarketing-Safety-Reporting-for-Human-Drug-and-Biological-Products-Including-Vaccines.pdf. cited 2021 May 12.
   Google Scholar
• Chen M, Vijay V, and Shi Q, et al. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011;16:697–703.
   PubMed Web of Science ®Google Scholar
• Chen M, Suzuki A, and Thakkar S, et al. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016;21:648–653.
   PubMed Web of Science ®Google Scholar
• Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother. 2014;58:6993–6995.
   PubMed Web of Science ®Google Scholar
• Pham AN, Bubalo JS, Lewis JS 2nd. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections. Mycoses. 2016;59:226–233.
   PubMed Web of Science ®Google Scholar
• Heinz WJ, Egerer G, Lellek H, et al. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses. 2013;56:304–310.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. The future of drug safety: promoting and protecting the health of the public. The National Academies Press: Washington, DC; 2007.
   Google Scholar